NTRB
Price
$9.11
Change
-$0.80 (-8.07%)
Updated
Jul 7, 11:29 AM (EDT)
Capitalization
110.3M
86 days until earnings call
REPL
Price
$9.79
Change
+$0.38 (+4.04%)
Updated
Jul 7, 12:50 PM (EDT)
Capitalization
724.62M
24 days until earnings call
Interact to see
Advertisement

NTRB vs REPL

Header iconNTRB vs REPL Comparison
Open Charts NTRB vs REPLBanner chart's image
Nutriband
Price$9.11
Change-$0.80 (-8.07%)
Volume$128
Capitalization110.3M
Replimune Group
Price$9.79
Change+$0.38 (+4.04%)
Volume$2.74K
Capitalization724.62M
NTRB vs REPL Comparison Chart in %
Loading...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTRB vs. REPL commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRB is a Buy and REPL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (NTRB: $9.91 vs. REPL: $9.40)
Brand notoriety: NTRB and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTRB: 169% vs. REPL: 45%
Market capitalization -- NTRB: $110.3M vs. REPL: $724.62M
NTRB [@Biotechnology] is valued at $110.3M. REPL’s [@Biotechnology] market capitalization is $724.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRB’s FA Score shows that 0 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • NTRB’s FA Score: 0 green, 5 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, REPL is a better buy in the long-term than NTRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRB’s TA Score shows that 3 TA indicator(s) are bullish while REPL’s TA Score has 3 bullish TA indicator(s).

  • NTRB’s TA Score: 3 bullish, 4 bearish.
  • REPL’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both NTRB and REPL are a bad buy in the short-term.

Price Growth

NTRB (@Biotechnology) experienced а +26.56% price change this week, while REPL (@Biotechnology) price change was -0.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.51%. For the same industry, the average monthly price growth was +14.00%, and the average quarterly price growth was -0.49%.

Reported Earning Dates

NTRB is expected to report earnings on Oct 01, 2025.

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+5.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($725M) has a higher market cap than NTRB($110M). NTRB YTD gains are higher at: 110.403 vs. REPL (-22.378). NTRB has higher annual earnings (EBITDA): -9.68M vs. REPL (-235.43M). REPL has more cash in the bank: 484M vs. NTRB (2.96M). NTRB has less debt than REPL: NTRB (282K) vs REPL (76.2M). NTRB has higher revenues than REPL: NTRB (2.4M) vs REPL (0).
NTRBREPLNTRB / REPL
Capitalization110M725M15%
EBITDA-9.68M-235.43M4%
Gain YTD110.403-22.378-493%
P/E RatioN/AN/A-
Revenue2.4M0-
Total Cash2.96M484M1%
Total Debt282K76.2M0%
FUNDAMENTALS RATINGS
NTRB vs REPL: Fundamental Ratings
NTRB
REPL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3655
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (26) in the Biotechnology industry is somewhat better than the same rating for NTRB (78) in the null industry. This means that REPL’s stock grew somewhat faster than NTRB’s over the last 12 months.

NTRB's Profit vs Risk Rating (94) in the null industry is in the same range as REPL (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to REPL’s over the last 12 months.

NTRB's SMR Rating (98) in the null industry is in the same range as REPL (98) in the Biotechnology industry. This means that NTRB’s stock grew similarly to REPL’s over the last 12 months.

NTRB's Price Growth Rating (36) in the null industry is in the same range as REPL (55) in the Biotechnology industry. This means that NTRB’s stock grew similarly to REPL’s over the last 12 months.

NTRB's P/E Growth Rating (100) in the null industry is in the same range as REPL (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTRBREPL
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
77%
Momentum
ODDS (%)
Bullish Trend 5 days ago
84%
Bearish Trend 5 days ago
83%
MACD
ODDS (%)
Bullish Trend 5 days ago
71%
Bearish Trend 5 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
77%
Bearish Trend 5 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
81%
Bearish Trend 5 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 27 days ago
88%
Bearish Trend 18 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
86%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TMDPX17.190.13
+0.76%
AMG TimesSquare Mid Cap Growth N
VCDAX191.271.14
+0.60%
Vanguard Consumer Discretionary Idx Adm
LMCLX8.820.05
+0.57%
Miller Income I
CIEQX12.720.02
+0.16%
Segall Bryant & Hamll Intl Eq Inst
HAONX15.540.02
+0.13%
Harbor International Core Investor

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and SONN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and SONN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-7.56%
SONN - NTRB
29%
Poorly correlated
-5.54%
RARE - NTRB
27%
Poorly correlated
+1.14%
REPL - NTRB
27%
Poorly correlated
-1.57%
STOK - NTRB
27%
Poorly correlated
-0.61%
DNLI - NTRB
25%
Poorly correlated
-1.41%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IDYA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-1.57%
IDYA - REPL
52%
Loosely correlated
+0.82%
SNDX - REPL
52%
Loosely correlated
N/A
XNCR - REPL
49%
Loosely correlated
+1.45%
CGON - REPL
48%
Loosely correlated
+0.82%
NRIX - REPL
48%
Loosely correlated
+2.33%
More